scFv(EPCAM)-41BB-CD3zeta CAR-T Lentivirus

Lentiviral vectors are the preferred vectors for CAR-T therapy because they possess the unique ability to directly integrate chimeric antigen receptor transgenes into the host genome, ensuring the delivery of the CAR construct to all progeny cells during T cell proliferation. This lentiviral system exhibits high safety, typically employing a third-generation self-inactivating design to minimize the risk of generating replicating lentiviruses. One of the main advantages of using a lentiviral platform is its high transduction efficiency across various T cell subsets, including CD4+ and CD8+ cells, which is crucial for constructing balanced and effective therapeutic products. Furthermore, the high yield of lentiviral particles enables consistent and reproducible experimental results. This integration is relatively stable, allowing for sustained expression of anti-EPCAM CARs.

The primary application of the scFv(EPCAM)-41BB-CD3zeta CAR-T lentivirus lies in the development and evaluation of adoptive cell therapies targeting epithelial cell adhesion molecule (EPCAM)-positive malignancies. EPCAM is a transmembrane glycoprotein frequently overexpressed in various solid tumors, including colorectal cancer, gastric cancer, breast cancer, lung cancer, and prostate cancer, while its expression is limited in normal epithelial tissues. This makes it an important target for CAR-T therapy. In a laboratory setting, this product can be used to perform in vitro cytotoxicity assays to evaluate the killing efficacy of CAR-T cells against various cancer cell lines. It also helps in studying the production of cytokines such as interferon-γ and tumor necrosis factor-α, which are indicators of T cell activation and inflammatory responses. In addition to simple killing assays, this CAR-T lentivirus is also crucial for preclinical in vivo studies in which modified human T cells are infused into xenograft mouse models to monitor tumor regression and long-term survival of CAR-T cells.